© 2001 European Society of Cardiology
Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations
a Danish Research Centre of Magnetic Resonance, Section 340, H:S Hvidovre Hospital, University of Copenhagen Kettegaard Allé 30, DK-2650 Hvidovre, Denmark
b Department of Cardiology and Endocrinology, H:S Frederiksberg Hospital, University of Copenhagen Copenhagen, Denmark
c Department of Medical Physiology, the Panum Institute, University of Copenhagen Copenhagen, Denmark
d Department of Clinical Physiology and Nuclear Medicine, H:S Rigshospitalet, University of Copenhagen Copenhagen, Denmark
* Corresponding author. Tel.: +45-36322978; fax: +45-36470302. E-mail address: bjoerng{at}dadlnet.dk (B.A. Groenning).
 |
Abstract |
|---|
Background: A range of neurohumoral substances have been suggested as diagnostic markers in heart failure. It is, however, undetermined which marker has the greatest diagnostic potential, and whether additional information is gained by a comprehensive neurohumoral evaluation.
Aims: The purpose of the study was to compare the value of epinephrine, norepinephrine, renin activity, aldosterone (ALDO), atrial (ANP) and brain (BNP) natriuretic peptides, arginine-vasopressin and endothelin (ENDO) as markers for left ventricular (LV) dimensions and ejection fraction (LVEF) in patients with systolic heart failure.
Methods: Forty-eight patients with symptomatic heart failure were examined with blood samples and magnetic resonance imaging along with 20 age and gender-matched normal controls.
Results: In multiple regression analyses, BNP was the strongest independent marker for LV end-diastolic (r=0.71, P<0.0001), and end-systolic (r=0.75, P<0.0001) volumes, myocardial mass (r=0.69, P<0.0001), and LVEF (r=–0.78, P<0.0001). ANP was a supplementary independent marker for LV end-diastolic (r=0.76, P<0.0001) and end-systolic (r=0.78, P<0.0001) (ANP and BNP combined) volumes, ENDO for myocardial mass [r=0.71, P<0.0001 (ENDO/BNP)], and ALDO for LVEF [r=–0.81, P<0.0001 (ALDO/BNP)].
Conclusion: BNP is the strongest marker for LV dimensions and LVEF in patients with systolic heart failure. However, a comprehensive neurohumoral evaluation may add some information to the diagnosis.
Key Words: Heart failure • Left ventricle • Diagnosis • Neurohormones • Natriuretic peptides • Magnetic resonance imaging
Received April 26, 2001; Accepted May 28, 2001
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Passino, R. Poletti, F. Bramanti, C. Prontera, A. Clerico, and M. Emdin Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure Eur J Heart Fail, January 1, 2006; 8(1): 46 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Avgeropoulou, I. Andreadou, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, and I. Kallikazaros The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine Eur J Heart Fail, August 1, 2005; 7(5): 882 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Daugaard, U. Lassen, P. Bie, E. B. Pedersen, K. T. Jensen, U. Abildgaard, B. Hesse, and A. Kjaer Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction Eur J Heart Fail, January 1, 2005; 7(1): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Williams, L. L. Ng, R. J. O'Brien, S. Taylor, D. J. Wright, and L.-B. Tan Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study Eur J Heart Fail, December 1, 2004; 6(7): 891 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Giannattasio, F. Achilli, M. Failla, A. Capra, A. Vincenzi, G. Gentile, D. Corsi, C. Zazzeron, L. Turolo, A. Morganti, et al. Arterial stiffness in heart failure patients: dependance on diastolic dysfunction and plasma aldosterone levels Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F30 - F34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Emdin, C. Marini, C. Passino, D. Giuggioli, B. Formichi, C. Ferri, J. Khabirinejad, R. Poletti, C. Prontera, A. Iervasi, et al. Right ventricular overload and cardiovascular neuroendocrine derangement in systemic sclerosis Eur. Heart J. Suppl., November 1, 2004; 6(suppl_F): F68 - F73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cochet, M. Zeller, Y. Cottin, C. Robert-Valla, A. Lalande, I. L'Huilllier, A. Comte, P. M. Walker, J. Desgres, J.-E. Wolf, et al. The extent of myocardial damage assessed by contrast-enhanced MRI is a major determinant of N-BNP concentration after myocardial infarction Eur J Heart Fail, August 1, 2004; 6(5): 555 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hammerer-Lercher, W. Ludwig, G. Falkensammer, S. Muller, E. Neubauer, B. Puschendorf, O. Pachinger, and J. Mair Natriuretic Peptides as Markers of Mild Forms of Left Ventricular Dysfunction: Effects of Assays on Diagnostic Performance of Markers Clin. Chem., July 1, 2004; 50(7): 1174 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G.F. Cleland and K. Goode Natriuretic peptides for heart failure. Fashionable? Useful? Necessary? Eur J Heart Fail, March 15, 2004; 6(3): 253 - 255. [Full Text] [PDF]
|
|
|
|
 |
|
 M.R Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, et al. Clinical applications of B-type natriuretic peptide (BNP) testing Eur. Heart J., October 1, 2003; 24(19): 1710 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Alehagen, G. Lindstedt, H. Eriksson, and U. Dahlstrom Utility of the Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma for the Evaluation of Cardiac Dysfunction in Elderly Patients in Primary Health Care Clin. Chem., August 1, 2003; 49(8): 1337 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Groenning, J. C. Nilsson, P. R. Hildebrandt, A. Kjaer, T. Fritz-Hansen, H. B.W. Larsson, and L. Sondergaard Neurohumoral prediction of left-ventricular morphologic response to {beta}-blockade with metoprolol in chronic left-ventricular systolic heart failure Eur J Heart Fail, October 1, 2002; 4(5): 635 - 646. [Abstract] [Full Text] [PDF]
|
|